Anabolic Interventions for Aging-Associated Sarcopenia
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
AGING in humans is associated with a progressive decrease in skeletal muscle mass and strength (sarcopenia) that contributes to frailty and falls. The age-associated changes in body composition result from lower levels of anabolic hormones, neuromuscular alterations, and a general decline in muscle protein turnover (1–3). The frailty of old age has emerged as an important public health problem because it impairs mobility and quality of life and increases the risk of falls and the use of health care resources (4–6). Therefore, recent years have witnessed a growing interest in the use of anabolic interventions for augmenting muscle mass and function in older men. The term sarcopenia, originally coined by Rosenberg (4) and recently reviewed by the National Institutes of Aging (5), refers to the involuntary loss of skeletal muscle mass and strength. This is in contrast to wasting, the involuntary loss of weight driven largely by inadequate nutrition, and cachexia, the involuntary loss of fat-free mass (FFM), especially body cell mass, generally resulting from a state of hypermetabolism and hypercatabolism (6). The etiology of sarcopenia is currently unknown. Holloszy (5) identified several possible mechanisms leading to sarcopenia, including loss of α motor neurons in the spinal column, impairment of endogenous growth hormone, androgen and estrogen production, inadequate protein intake, dysregulation of catabolic cytokines, and reduced physical activity. Mortality in the elderly is primarily associated with atherosclerosis, cancer, and dementia. In an increasing number of the elderly men and women, however, loss of muscle mass and strength is an important determinant of the individual’s ability to live an independent life (7). There is no consensus on whether sarcopenia should be viewed as a disease or process of normative aging (4). It has been argued that, because loss of muscle mass occurs even during the course of successful aging, sarcopenia should be considered a disease only when it induces disability (4). There is also no consensus on what threshold of muscle loss should be used to define sarcopenia. The magnitude of the public health problem posed by sarcopenia is not known (8). Baumgartner et al. (9) examined the prevalence of sarcopenia in Hispanic and non-Hispanic white elderly men and women in New Mexico. Sarcopenia was defined as the relative muscle mass that was two sds below the sex-specific means of the Rosetta Study reference data (10) for young adults, aged 18–40 yr. The study (9) demonstrated that the prevalence of sarcopenia increased from 13% to 24% in persons under 70 years of age. Nearly half of all persons over 80 years of age met this definition of sarcopenia. The study also demonstrated that sarcopenia was associated with a 3- to 4-fold increased likelihood of disability in elderly people, independently of age, sex, obesity, ethnicity, socioeconomic status, chronic morbidity, and health behaviors (9). Another cross-sectional survey performed by Melton (11) in Olmsted County in Minnesota used slightly different thresholds for defining sarcopenia and reported lower prevalence rates. Based on an age-stratified, random sample of the population of Rochester, Minnesota, this survey verified the findings of Baumgartner et al. (9) that lean body mass decreases progressively after the second decade of life in both men and women. Age-related losses in fat-free mass, appendicular muscle mass, and total muscle mass are all linear in both men and women, and there was no significant difference in the slope of the regression line before 50 and after 50 years of age. The prevalence of sarcopenia in individuals over 20 years of age was 2–3% and in those over 65 years of age, approximately 10% (11). Taken together, these two epidemiological studies provide evidence that sarcopenia is an important public health problem. In the two-compartment model of body composition, body weight is the combination of fat mass and fat-free mass. Fat-free mass, in turn, is the combination of body cell mass, extracellular fluid, and the extracellular solids such as collagen and bone mineral. Body cell mass can be further divided into the fat-free portion of cells within muscle, viscera, and the immune system. Muscle cell mass is an important determinant of muscle strength, whereas the sum of visceral and muscle body cell mass predicts energy requirements (6). Thus, changes in body composition with aging, especially in the FFM component, have important implications for functional status and survival (6, 13). Weight gain in adults is associated with an increase in absolute and percent fat mass (14). In women, body weight increases between the ages of 40 and 50 yr and remains stable thereafter; percent body fat is also stable until 40 yr of age and increases from 28% to 35% between 40 and 50 yr of age (15). In another cross-sectional study (16) of men and women 18–85 yr of age who used total body potassium, percent fat incr
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
Exercise training and nutritional supplementation for physical frailty in very elderly people
Fiatarone, M. A., O'Neill, E. F., Ryan, N. D., Clements, K. M., Solares, G. R., Nelson, M. E., Roberts, S. B., Kehayias, J. J., Lipsitz, L. A., & Evans, W. J. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406233302501 · Cited by 2,857
Sarcopenia: origins and clinical relevance
Rosenberg, I. H. (1997) · The Journal of Nutrition · doi:10.1093/jn/127.5.990s · Cited by 2,399 · cited 3×
“The term sarcopenia, originally coined by Rosenberg (4) and recently reviewed by the National Institutes of Aging (5), refers to the involuntary loss of skeletal muscle mass and strength.”
BackgroundThe effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
Bhasin, S., Storer, T. W., Berman, N., Callegari, C., Clevenger, B., Phillips, J., Bunnell, T. J., Tricker, R., Shirazi, A., & Casaburi, R. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607043350101 · Cited by 1,659
Self-citationHigh-Intensity Strength Training in Nonagenarians: Effects on Skeletal Muscle
Fiatarone, M. A. (1990) · JAMA · doi:10.1001/jama.1990.03440220053029 · Cited by 1,593
ORENTREICH, N., BRIND, J. L., RIZER, R. L., & VOGELMAN, J. H. (1984) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-59-3-551 · Cited by 1,349
Salomon, F., Cuneo, R. C., Hesp, R., & Sönksen, P. H. (1989) · New England Journal of Medicine · doi:10.1056/nejm198912283212605 · Cited by 1,326
Human aging, muscle mass, and fiber type composition.
Evans, W. J., & Lexell, J. (1995) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/50a.special_issue.11 · Cited by 1,308
Appendicular skeletal muscle mass: effects of age, gender, and ethnicity
Gallagher, D., Visser, M., De Meersman, R. E., Sepúlveda, D., Baumgartner, R. N., Pierson, R. N., Harris, T., & Heymsfield, S. B. (1997) · Journal of Applied Physiology · doi:10.1152/jappl.1997.83.1.229 · Cited by 966
Leg extensor power and functional performance in very old men and women.
Bassey, E. J., Fiatarone, M. A., O'neill, E. F., Kelly, M., Evans, W. J., & Lipsitz, L. A. (1992) · Clinical Science · doi:10.1042/cs0820321 · Cited by 943 · cited 1×
“Leg weakness and decreased peak torque and power are associated with impaired gait characteristics, such as small steps and slow speeds (35) and a history of falling (36, 37).”
Background
Cited by
The Decline of Androgen Levels in Elderly Men and Its Clinical and Therapeutic Implications
Kaufman, J. M., & Vermeulen, A. (2005) · Endocrine Reviews · doi:10.1210/er.2004-0013 · Cited by 1,079
Systemic effects of chronic obstructive pulmonary disease
Agustí, A. G. N., Noguera, A., Sauleda, J., Sala, E., Pons, J., & Busquets, X. (2003) · European Respiratory Journal · doi:10.1183/09031936.03.00405703 · Cited by 1,045
Basal Muscle Amino Acid Kinetics and Protein Synthesis in Healthy Young and Older Men
Volpi, E. (2001) · JAMA · doi:10.1001/jama.286.10.1206 · Cited by 416
Current Concepts in Anabolic-Androgenic Steroids
Evans, N. A. (2004) · The American Journal of Sports Medicine · doi:10.1177/0363546503262202 · Cited by 379
Testosterone supplementation therapy for older men: potential benefits and risks
Gruenewald, D. A., & Matsumoto, A. M. (2003) · Journal of the American Geriatrics Society · doi:10.1034/j.1601-5215.2002.51018.x · Cited by 279
Metadata
- Authors
- Bross, R.
- Venue
- Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1999-10-01
- Volume
- 84
- Issue
- 10
- Pages
- 3420-3430
- ISSN
- 0021-972X (ISSN-L)
- OpenAlex
- W2051164291
- Cited by
- 76
- References
- 32
- FWCI
- 1.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anabolic Interventions for Aging-Associated Sarcopenia. https://app.cochat.ai/papers/10.1210/jc.84.10.3420
- The paper
- Bross, R. (1999). Anabolic Interventions for Aging-Associated Sarcopenia. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.84.10.3420
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.